SignalHF vs Viz AAA
AI Verdict
Choose SignalHF if…
Choose SignalHF if your primary goal is to proactively manage chronic heart failure patients equipped with cardiac implantable electronic devices (CIEDs) and reduce rehospitalization rates. This tool is ideal for cardiology practices seeking an FDA-cleared AI solution to predict heart failure exacerbations within 30 days, enabling timely interventions and personalized care plans based on continuous device data analysis.
View SignalHF →Choose Viz AAA if…
Choose Viz AAA if your institution requires rapid, AI-powered detection and triage of suspected Abdominal Aortic Aneurysm (AAA) directly from CT angiography scans. This solution is best suited for emergency departments, radiology, and vascular surgery teams aiming to accelerate diagnosis, streamline care coordination, and improve treatment decisions for acute aortic pathologies.
View Viz AAA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools emphasize seamless integration into existing hospital workflows and aim to streamline processes for healthcare professionals. SignalHF centralizes and standardizes cardiac implantable device data, while Viz AAA integrates with PACS and EHR systems and offers a HIPAA-compliant communication platform with mobile access. Without direct user feedback or comparative studies on their interfaces, it's difficult to definitively pick a winner.
Clinical Value
TieBoth SignalHF and Viz AAA are FDA-cleared AI solutions designed to improve patient outcomes by enabling earlier detection and intervention for critical conditions. SignalHF predicts heart failure hospitalizations within 30 days, aiming to reduce hospital admissions. Viz AAA detects and triages suspected abdominal aortic aneurysms from CT scans, accelerating diagnosis and care coordination. Both have published clinical validation studies supporting their efficacy.
Pricing & Value
TieBoth companies do not publicly disclose specific pricing, requiring direct contact for quotes. Viz AAA is noted to be an enterprise-level subscription, costing over $25,000 per year per hospital and not accessible to individual physicians. SignalHF also requires contacting the vendor for pricing. Without transparent pricing details for either, it is not possible to determine which offers better value.
Enterprise Readiness
Viz AAAViz AAA demonstrates stronger enterprise readiness with its deployment in nearly 2,000 hospitals in the U.S. and Europe, covering over 230 million lives. It also offers a broader platform with over 50 FDA-cleared algorithms across multiple specialties, indicating a more comprehensive and scalable solution for large healthcare systems. SignalHF, while FDA-cleared and manufacturer-agnostic, does not provide comparable metrics for its adoption or breadth of deployment.
Innovation
Viz AAAViz.ai, the company behind Viz AAA, is recognized as a pioneer in AI algorithms for rapid diagnosis and care coordination, with over 50 FDA-cleared algorithms across various medical imaging data. Their platform extends beyond a single condition, offering a comprehensive suite for multiple pathologies and a focus on real-time care coordination. SignalHF is innovative as the first pacemaker-compatible heart failure algorithm, but its scope appears more specialized compared to Viz.ai's broader platform approach.
Support & Docs
Viz AAAViz.ai provides extensive resources including customer support, user guides, Viz Academy, clinical validation studies, and a trust center. They also emphasize dedicated 24/7 on-call specialists. While SignalHF is FDA-cleared and provides instructions for use, there is less publicly available information regarding their comprehensive support and documentation offerings compared to Viz.ai.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | Viz AAA |
|---|---|---|
| Product Name | SignalHF | Viz AAA |
| Company | Implicity | Viz.ai |
| Description | SignalHF by Implicity is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. | Viz AAA is the first FDA-cleared AI-powered solution by Viz.ai for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans, designed to accelerate diagnosis and care coordination. |
| Key Functionality | Predicts heart failure hospitalizations within 30 days by analyzing data from cardiac implantable electronic devices (CIEDs) | Detects and triages suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans |
| Data Sources Analyzed | Physiological data, demographics, lead measurements, episodes, and therapies from various CIEDs (pacemakers, ICDs, CRTs) | CT angiography (CTA) scans |
| Alerts | Generates automatic alerts for care teams based on risk scores | Real-time alerts to care teams |
| Compatibility | Manufacturer-agnostic compatibility with various CIEDs (Biotronik, Boston Scientific, and Medtronic pacemakers, ICDs, CRTs) | From any scanner in a hospital network |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and Viz AAA.